



## **Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014**

**March 6, 2014 1:30 PM EST**

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-866-271-6130 (domestic) or 1-617-213-8894 (international) and provide the access code 13838305. The live webcast can be accessed under "Investor Events" in the Investors section of the Company's website at [www.iderapharma.com](http://www.iderapharma.com) or you may use the link <http://edge.media-server.com/m/p/tni65ic2/lan/en>.

A replay of the call will be available at 12:30 p.m. EDT on March 13, 2014 until 11:59 p.m. EDT on March 20, 2014. To access the replay, please dial 1-888-286-8010 (domestic) or 1-617-801-6888 (international) and reference the access code 11389237. The archived webcast will be available for 30 days in the Investors section of Idera's website at [www.iderapharma.com](http://www.iderapharma.com).

### **About Idera Pharmaceuticals, Inc.**

Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). Idera is developing these therapeutics for the treatment of genetically defined forms of B-cell lymphoma and for autoimmune diseases with orphan indications. In addition to its TLR programs, Idera is developing gene silencing oligonucleotides that it has created using its proprietary technology, to inhibit the production of disease-associated proteins by targeting RNA.

Source: Idera Pharmaceuticals, Inc.

### **Investor Contact:**

Stern Investor Relations, Inc.  
Sarah McCabe, 267-909-9237  
[sarah@sternir.com](mailto:sarah@sternir.com)